newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Continued progress in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with 35% of expected enrollment completed, on track to